Drug Type Small molecule drug |
Synonyms Telmisartan/Sitagliptin, HDDO-1609, HDDO-16091 + HDDO-16092 + [1] |
Target |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC16H20F6N5O6P |
InChIKeyGQPYTJVDPQTBQC-KLQYNRQASA-N |
CAS Registry654671-77-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hypertension | Phase 1 | KR | 11 Jan 2019 | |
Diabetes Mellitus | Phase 1 | KR | 08 Jan 2019 |